Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a cutting-edge biotechnology company dedicated to the development of engineered cells as medicines to treat various diseases. Sana's primary focus is on cell and gene therapy, aiming to harness the potential of engineered cells to bring about transformative changes in healthcare.
The company is advancing a range of innovative therapeutic programs across multiple indications with unmet medical needs. Some of the key areas of focus include oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system (CNS) disorders. Sana's pipeline includes promising candidates such as SC291, SC262, SC255, and UP421, which are at various stages of development.
Recent Achievements and Projects:
- Hypoimmune Technology: Sana's proprietary hypoimmune (HIP) platform is designed to create cells that can evade the patient’s immune system, allowing for the transplant of allogeneic cells without the need for immunosuppression.
- CAR T Cell Therapies: The company is developing novel CAR T cell therapies for various cancers and autoimmune diseases. Preclinical data have shown that HIP-modified CAR T cells can avoid immune detection while retaining their functionality and anti-tumor effects.
- Pluripotent Stem Cells: Sana is also focused on differentiating pluripotent stem cells ex vivo into immune-cloaked functional cells, aiming to replace any missing or damaged cells in the body.
- Preclinical and Clinical Studies: In recent studies, Sana has demonstrated significant progress, such as the successful evasion of immune detection by HIP-modified CAR T cells and the potential for HIP-modified pancreatic islet cells to achieve insulin independence in diabetic models.
- Partnerships: The company collaborates with leading research institutions and organizations to further its mission of developing next-generation cell and gene therapies.
Sana Biotechnology operates out of multiple locations, including Seattle, Cambridge, South San Francisco, and Rochester, and is committed to advancing its pipeline of therapies to address critical healthcare challenges.
Sana Biotechnology (NASDAQ: SANA) announced that the FDA has granted Fast Track designation for SC291, their hypoimmune-modified CD19-directed allogeneic CAR T therapy, for treating relapsed/refractory systemic lupus erythematosus (SLE). The company is currently enrolling patients in the GLEAM trial, which evaluates SC291 in B-cell mediated autoimmune diseases including lupus nephritis, extrarenal lupus, and ANCA-associated vasculitis. Initial clinical data is expected in 2025. SC291's scaled manufacturing process can produce hundreds of patient doses per manufacturing run, positioning it as a potential universal off-the-shelf therapy.
Sana Biotechnology (NASDAQ: SANA) has announced its participation in two major investor conferences this December. The company's President and CEO, Steve Harr, will deliver business overviews and updates at both events. The first presentation will be a panel participation at Citi's 2024 Global Healthcare Conference on December 3 at 2:30 p.m. ET, followed by a presentation at the 7th Annual Evercore ISI HealthCONx Conference on December 4 at 2:35 p.m. ET. Both presentations will be available via webcast on Sana's website, with replays accessible for 30 days after the events.
Sana Biotechnology (NASDAQ: SANA) reported Q3 2024 financial results with a cash position of $199.0 million and runway into 2026. The company is advancing three clinical trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology. Q3 net loss was $59.9 million ($0.25 per share). Research and development expenses decreased to $53.2 million from $65.6 million in Q3 2023. The company expects to share clinical data from multiple trials in 2024 and 2025, while focusing on immunologic diseases development.
Sana Biotechnology (NASDAQ: SANA) announced a strategic shift to focus on type 1 diabetes and B-cell mediated autoimmune diseases. The company will suspend development of SC291 in oncology and SC379 glial progenitor cell program, seeking partnerships for these initiatives. The restructuring extends cash runway into 2026, though 2024 operating cash burn may exceed previous $200 million guidance.
The company will prioritize development of UP421 (HIP-modified islet cells), SC291 (for autoimmune diseases), SC262 (for refractory B-cell malignancies), and the fusogen platform. Clinical proof of concept data is expected across multiple studies in 2024 and 2025.
Sana Biotechnology (NASDAQ: SANA), a company specializing in engineered cells for patient treatment, has announced its participation in the Goldman Sachs Cell Therapy Day Conference. The event will take place on Tuesday, October 1, 2024, with Sana's panel scheduled for 1:00 p.m. ET.
Steve Harr, Sana's President and CEO, will present a business overview and update during the panel. The presentation will be webcast live and accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of the presentation will remain available on the website for 30 days following the conference.
This participation provides an opportunity for investors and interested parties to gain insights into Sana Biotechnology's current operations and future plans in the field of engineered cell therapies.
Sana Biotechnology (NASDAQ: SANA), a company specializing in engineered cells for patient treatment, has announced its participation in three major investor conferences in September 2024. The company will present at:
- The Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 at 11:30 a.m. ET
- The 2024 Wells Fargo Healthcare Conference on September 5 at 3:00 p.m. ET
- The HC Wainwright 26th Annual Global Investment Conference on September 9 at 12:30 p.m. ET
Each presentation will include a business overview and update. Webcasts will be available on Sana's Investor Relations website, with replays accessible for 30 days following each conference.
Flagship Pioneering and Quotient Therapeutics have announced a collaboration with Pfizer to identify potential novel targets for cardiovascular and renal diseases. This agreement, initiated under the strategic partnership between Flagship Pioneering and Pfizer, leverages Quotient's Somatic Genomics platform to analyze somatic mutations in diseased patient tissue.
The collaboration involves two research programs aimed at discovering and developing transformative therapies. Pioneering Medicines, Flagship's in-house drug discovery unit, will lead the strategic partnership with Pfizer. This initiative represents a significant milestone in the partnership and highlights the potential of collaboration to accelerate therapeutic innovation in addressing cardiovascular and renal diseases, which are leading causes of mortality and morbidity worldwide.
Sana Biotechnology (NASDAQ: SANA) has appointed Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Patel brings extensive experience in drug development and clinical research, having contributed to the advancement of 10 FDA-approved treatments. His expertise in immunology and autoimmune diseases aligns with Sana's focus on engineered cells and its clinical pipeline, particularly for B-cell mediated autoimmune diseases and type 1 diabetes.
Previously, Dr. Patel served as EVP and CSO at UCB, where he played a key role in pipeline transformation. He also spent 10 years at Novartis, leading research in autoimmune, transplantation, and inflammation disease areas. Sana currently has four ongoing clinical trials across seven indications, positioning the company to advance its mission of developing innovative therapies for patients in need.
Sana Biotechnology (NASDAQ: SANA) reported its second quarter 2024 financial results and business updates. The company is advancing its hypoimmune technology in trials for oncology, B-cell mediated autoimmune diseases, and type 1 diabetes. Key trials include the GLEAM trial for SC291 in autoimmune diseases, ARDENT and VIVID trials for SC291 and SC262 in oncology, with initial data expected in 2024. Sana published promising preclinical data in Nature Biotechnology.
Financially, Sana reported a cash position of $251.6 million and expects a 2024 operating cash burn below $200 million. R&D expenses for Q2 2024 were $60.9 million, down from $73.0 million in Q2 2023. G&A expenses were $16.4 million. The net loss for Q2 2024 was $50.3 million ($0.21 per share), improved from $114.0 million ($0.59 per share) in Q2 2023.
MSCI Inc. (NYSE: MSCI) has appointed Michelle Seitz to its Board of Directors, effective August 5, 2024. Seitz, the former Chair and CEO of Russell Investments, will serve as a member of the Audit and Risk Committee. With over three decades of experience in asset management and private wealth, Seitz is currently the Founder and CEO of MeydenVest Partners. Her appointment follows an extensive search initiated last year.
MSCI's Chairman and CEO, Henry A. Fernandez, highlighted Seitz's deep industry experience and her track record of driving transformational growth while fostering a client-centric culture. Seitz expressed enthusiasm about joining MSCI's mission to bring greater transparency to financial markets. Her diverse background includes leadership roles at William Blair, where she led significant growth in the firm's asset and wealth management division.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
What does Sana Biotechnology, Inc. do?
What is the company's primary focus?
What is the hypoimmune (HIP) platform?
What are some of Sana's key therapeutic areas?
What recent achievements has Sana Biotechnology made?
Where is Sana Biotechnology located?
What is SC262?
What is the significance of the hypoimmune platform?
How is Sana Biotechnology advancing its CAR T cell therapies?
How can I find more information about Sana Biotechnology?
